Stockscreener 앱 받기
4.72
2.61%
0.12
시간 외 거래:
4.70
-0.02
-0.42%
전일 마감가:
$4.60
열려 있는:
$4.51
하루 거래량:
705.31K
Relative Volume:
6.98
시가총액:
$36.21M
수익:
$52.29M
순이익/손실:
$-73.52M
주가수익비율:
-5.8272
EPS:
-0.81
순현금흐름:
$-100.45M
1주 성능:
-13.24%
1개월 성능:
-34.26%
6개월 성능:
-51.69%
1년 성능:
-56.31%
1일 변동 폭
$4.51
$5.0082
1주일 범위
$4.13
$5.46
52주 변동 폭
$4.13
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
명칭
Precision Biosciences Inc
전화
919-314-5512
주소
302 EAST PETTIGREW STREET, DURHAM, NC
DTIL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.72 | 36.21M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-30 | 개시 | Guggenheim | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-06-09 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 재개 | BTIG Research | Buy |
| 2020-04-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-05 | 개시 | Stifel | Buy |
| 2020-02-25 | 개시 | William Blair | Outperform |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | H.C. Wainwright | Buy |
| 2019-04-22 | 개시 | Barclays | Overweight |
| 2019-04-22 | 개시 | Goldman | Buy |
| 2019-04-22 | 개시 | JP Morgan | Overweight |
| 2019-04-22 | 개시 | Jefferies | Buy |
모두보기
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial - Yahoo Finance
Precision BioSciences gets nod for HBV trial in Hong Kong - Investing.com
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B - Business Wire
Precision BioSciences stock hits 52-week low at $5.2 By Investing.com - Investing.com Nigeria
Precision BioSciences stock hits 52-week low at $5.2 - Investing.com India
(DTIL) Proactive Strategies - Stock Traders Daily
Precision BioSciences' SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com UK
Precision BioSciences stock hits 52-week low at $6.4 By Investing.com - Investing.com South Africa
Precision BioSciences stock hits 52-week low at $6.4 - Investing.com
Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 11.8% in November - MarketBeat
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More - Yahoo Finance
Precision BioSciences (NASDAQ:DTIL) Trading 3.6% HigherHere's What Happened - MarketBeat
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN
Insider Buying: John Kelly Acquires Shares of Precision BioScien - GuruFocus.com
Precision BioSciences to Participate in Upcoming November Investor Conferences - BioSpace
Precision BioSciences to Present at Two Major Gene Editing Conferences in November | DTIL Stock News - StockTitan
Trading (DTIL) With Integrated Risk Controls - Stock Traders Daily
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B - Business Wire
JANUS HENDERSON GROUP PLC's Strategic Acquisition in Precision B - GuruFocus.com
Precision BioSciences stock hits 52-week low at $7.94 By Investing.com - Investing.com Canada
Precision BioSciences stock hits 52-week low at $7.94 - Investing.com
Highbridge Capital Management's Strategic Acquisition of Precisi - GuruFocus.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PR Newswire
What is HC Wainwright's Forecast for DTIL FY2024 Earnings? - MarketBeat
Research Analysts Offer Predictions for DTIL FY2027 Earnings - MarketBeat
(DTIL) Technical Data - Stock Traders Daily
Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 - Investing.com India
Precision Biosciences' general counsel sells $4,815 in stock - Investing.com
Precision Biosciences' general counsel sells $4,815 in stock By Investing.com - Investing.com UK
Precision BioSciences keeps $34 target, Market Perform rating By Investing.com - Investing.com Australia
Precision BioSciences: Q3 Earnings Snapshot - Darien Times
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Precision BioSciences keeps $34 target, Market Perform rating - Investing.com
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com
Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat
Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace
Precision Biosciences Inc (DTIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Precision Biosciences Inc 주식 (DTIL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Scimeca Dario | General Counsel and Secretary |
Nov 02 '24 |
Option Exercise |
0.00 |
1,836 |
0 |
8,557 |
| Scimeca Dario | General Counsel and Secretary |
Nov 04 '24 |
Sale |
8.19 |
588 |
4,816 |
7,969 |
| Amoroso Michael | President and CEO |
Nov 04 '24 |
Sale |
8.19 |
3,012 |
24,668 |
28,537 |
2.88%
2.65%
자본화:
|
볼륨(24시간):